LY686017: neurokinin 1 receptor (NK1R) antagonist, a possible therapy for alcoholism; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 9916461 |
| CHEMBL ID | 3544984 |
| SCHEMBL ID | 2898629 |
| MeSH ID | M0519704 |
| Synonym |
|---|
| (2-(1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1h-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone |
| tradipitant [inn] |
| tradipitant [who-dd] |
| tradipitant [usan] |
| {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chloro-phenyl)-methanone |
| {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl ]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| ly-686017 |
| unii-ny0coc51fi |
| tradipitant [usan:inn] |
| methanone, (2-(1-((3,5-bis(trifluoromethyl)phenyl)methyl)-5-(4-pyridinyl)-1h-1,2,3-triazol-4-yl)-3-pyridinyl)(2-chlorophenyl)- |
| ly686017 |
| ny0coc51fi , |
| vly-686 |
| tradipitant , |
| 622370-35-8 |
| SCHEMBL2898629 |
| (2-(1-(3,5-bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1h-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone |
| gtpl9278 |
| HY-16732 |
| CS-8056 |
| CHEMBL3544984 |
| vly686 |
| [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone |
| vly 686 |
| ly 686017 |
| AKOS027422691 |
| tradipitant(vly-686) |
| mfcd28127604 |
| DB12580 |
| FT-0703806 |
| AS-35293 |
| Q1798493 |
| BCP30446 |
| ly686017; ly 686017; ly686017; vly 686; vly686; vly686 |
| SB18893 |
| tradipitant (usan/inn) |
| D11728 |
| A915947 |
| DTXSID801045805 |
| AC-36943 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| quinoxalines | mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | ||
| substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | 2008 | 2010 | 15.0 | medium | 1 | 0 | 0 | 2 | 0 | 0 | |
| paroxetine | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| triazoles | 1,2,3-triazole | 2008 | 2011 | 15.0 | high | 2 | 0 | 0 | 5 | 1 | 0 | ||
| gr 73632 | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |||
| varenicline | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| naltrexone | cyclopropanes; morphinane-like compound; organic heteropentacyclic compound | antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcohol Abuse | 0 | 2008 | 2009 | 15.8 | high | 1 | 0 | 0 | 4 | 0 | 0 | |
| Alcohol Drinking | 0 | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Alcoholism | 1 | 2008 | 2009 | 15.8 | high | 1 | 0 | 0 | 4 | 0 | 0 | |
| Anxiety Disorders | 0 | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Anxiety Neuroses | 0 | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Recrudescence | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Article | Year |
|---|---|
| Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 20, Issue:2 | 2010 |